$50.0M
1 filing since 2025 · latest Equity filed
Latigo Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of non-opioid pain medicines. Based in Thousand Oaks, CA, the company leverages advanced technologies, including artificial intelligence and machine learning, to create innovative treatments that address the unmet needs in pain management.
What sets it apart
Latigo Biotherapeutics stands out by focusing on the fundamental mechanisms of pain transduction, offering patients safer alternatives to traditional pain management solutions while minimizing dependency risks.
LTG-001 is Latigo Biotherapeutics' lead candidate that aims to provide effective non-opioid pain relief. Successfully navigating Phase 1 clinical trials, it addresses the root causes of pain without the associated risks of addiction linked to opioid medications.
